Toulany M, Rodemann H P
Dept. of Radiation Oncology, Eberhard-Karls University, 72076 Tuebingen, Roentgenweg 11, Germany.
Nuklearmedizin. 2010;49 Suppl 1:S26-30.
Accumulated evidence indicates that activation of erbB family of receptors, when mutated or over-expressed, mediates chemo- and radiotherapy resistance. In this context signaling pathways down-stream of epidermal growth factor receptor (EGFR), when abnormally activated, invoke cell survival mechanisms, which leads to resistance against radiation. In several reports it has been demonstrated that molecular targeting of EGFR signaling enhances the cytotoxic effects of radiotherapy. The radiosensitizing effects of EGFR antagonists correlate with a suppression of the ability of tumor cells to repair radiation-induced DNA double strand breaks (DNA-DSBs) through non-homologous end-joining repair pathway (NHEJ). The purpose of this review is to highlight the function of EGFR and erbB2 receptors on signaling pathways, i. e. PI3K/Akt activated by ionizing radiation (IR) and involved in repair of DNA-DSB which can explain the radiosensitizing effects of related antagonists. Advances in understanding the mechanism of erbB-signaling in regulating DNA-DSB repair will promote translational approaches to test new strategies for clinically applicable molecular targeting.
越来越多的证据表明,erbB受体家族发生突变或过度表达时被激活,可介导化疗和放疗抗性。在这种情况下,表皮生长因子受体(EGFR)下游的信号通路异常激活时,会引发细胞存活机制,从而导致对辐射产生抗性。在多篇报道中已证实,EGFR信号通路的分子靶向作用可增强放疗的细胞毒性作用。EGFR拮抗剂的放射增敏作用与抑制肿瘤细胞通过非同源末端连接修复途径(NHEJ)修复辐射诱导的DNA双链断裂(DNA-DSBs)的能力相关。本综述的目的是强调EGFR和erbB2受体在信号通路中的功能,即电离辐射(IR)激活并参与DNA-DSB修复的PI3K/Akt信号通路,这可以解释相关拮抗剂的放射增敏作用。在理解erbB信号通路调节DNA-DSB修复机制方面取得的进展,将推动转化研究,以测试临床适用的分子靶向新策略。